Aligos Therapeutics: Promising Developments in Liver Disease Programs and Strategic Pipeline Drive Buy Rating
I'm PortAI, I can summarize articles.
Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating for Aligos Therapeutics, maintaining a $50 price target. The rating is based on promising developments in Aligos' liver disease programs, including successful Phase 1 trial results for pevifoscorvir sodium and ALG-055009. These advancements, along with a favorable safety profile and strategic partnerships, support the company's pipeline. The valuation model uses a risk-adjusted methodology, acknowledging potential clinical and regulatory risks.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments